ArticleFrontiers in oncology2026
Logistic regression-based model for differential diagnosis between plasma cell mastitis and non-mass type breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a diagnostic model for differentiating plasma cell mastitis (PCM) from non-mass type breast cancer (NMTBC) to facilitate clinical decision-making and reduce unnecessary invasive biopsies. Methods: A total of 120 patients with pathologically confirmed non-mass breast lesions (60 with PCM and 60 with NMTBC) were retrospectively included. Clinical and multimodal ultrasound features were assessed. Univariate analysis was performed to identify variables with differential diagnostic value. The dataset was randomly divided into a training set and a test set at a 7:3 ratio, and an elastic net regularized logistic regression model was constructed based on the training set. The diagnostic performance was validated in the independent test set, and the final model was visualized as a nomogram. Results: The regularized logistic regression model ultimately incorporated eight features: age, lesion intensity, location, calcification, resistive index (RI), spiculated margin, posterior acoustic features, and elastography score. In the testing set, the model achieved an area under the receiver operating characteristic curve (AUC) of 0.969 (95% CI: 0.921-1.000), with a sensitivity of 88.9% (95% CI: 67.2-96.9%), a specificity of 94.4% (95% CI: 74.2-99.0%), an accuracy of 91.7% (95% CI: 78.2-97.1%), a positive predictive value of 94.1% (95% CI: 73.0-99.0%), and a negative predictive value of 89.5% (95% CI: 68.6-97.1%). Conclusion: The proposed model effectively differentiates PCM from NMTBC, serving as a reliable clinical tool to help minimize unnecessary biopsies for benign lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.